IDO activation, inflammation and musculoskeletal disease-Reference-Cited by-同舟云学术

IDO activation, inflammation and musculoskeletal disease

Published:2020-03 Issue: Volume:131 Page:110820
ISSN:0531-5565
Container-title:Experimental Gerontology
language:en
Short-container-title:Experimental Gerontology

Author:

Ogbechi Joy,Clanchy Felix I.,Huang Yi-Shu,Topping Louise M.,Stone Trevor W.,Williams Richard O.

Funder

Cancer Research UK

Ministry of Science and Technology, Taiwan

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Genetics,Molecular Biology,Aging,Biochemistry

Reference103 articles.

1. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects;Alesci;Neuroimmunomodulation,2005

2. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes;Angiolilli;Ann. Rheum. Dis.,2017

3. Interferon (IFN)-gamma-mediated inflammation and the kynurenine pathway in relation to bone mineral density: the Hordaland Health Study;Apalset;Clin. Exp. Immunol.,2014

4. Altered gene expression profiles of histone lysine methyltransferases and demethylases in rheumatoid arthritis synovial fibroblasts;Araki;Clin. Exp. Rheumatol.,2018

5. Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements;Badawy;Neuropharmacology,2017

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of 2-benzylsulfinyl-benzoxazoles as potent and selective indoleamine 2,3-dioxygenase 1 inhibitors to combat inflammation;Bioorganic Chemistry;2024-11

2. The kynurenine pathway in patients with rheumatoid arthritis during tumor necrosis factor α inhibitors treatment;Rheumatology;2024-08-27

3. Taking advantage of the interaction between the sulfoxide and heme cofactor to develop indoleamine 2, 3-dioxygenase 1 inhibitors;Bioorganic Chemistry;2024-07

4. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases;Cell Death Discovery;2024-05-02

5. The Biologic IRL201805 Alters Immune Tolerance Leading to Prolonged Pharmacodynamics and Efficacy in Rheumatoid Arthritis Patients;International Journal of Molecular Sciences;2024-04-16